| Literature DB >> 33136197 |
Peter Rugbjerg1,2, Lisbeth Olsson3.
Abstract
Unfavorable cell heterogeneity is a frequent risk during bioprocess scale-up and characterized by rising frequencies of low-producing cells. Low-producing cells emerge by both non-genetic and genetic variation and will enrich due to their higher specific growth rate during the extended number of cell divisions of large-scale bioproduction. Here, we discuss recent strategies for synthetic stabilization of fermentation populations and argue for their application to make cell factory designs that better suit industrial needs. Genotype-directed strategies leverage DNA-sequencing data to inform strain design. Self-selecting phenotype-directed strategies couple high production with cell proliferation, either by redirected metabolic pathways or synthetic product biosensing to enrich for high-performing cell variants. Evaluating production stability early in new cell factory projects will guide heterogeneity-reducing design choices. As good initial metrics, we propose production half-life from standardized serial-passage stability screens and production load, quantified as production-associated percent-wise growth rate reduction. Incorporating more stable genetic designs will greatly increase scalability of future cell factories through sustaining a high-production phenotype and enabling stable long-term production.Entities:
Keywords: Evolutionary stability; Genetic heterogeneity; Metabolic burden; Phenotypic heterogeneity; Production load; Production robustness; Production stability
Mesh:
Year: 2020 PMID: 33136197 PMCID: PMC7695646 DOI: 10.1007/s10295-020-02325-0
Source DB: PubMed Journal: J Ind Microbiol Biotechnol ISSN: 1367-5435 Impact factor: 3.346
Fig. 1Production over time may change due to non-genetic and genetic heterogeneity as well as homogenetic change. Five hypothetical heterogeneity scenarios are presented in relation to, a bulk-population performance, b bulk population-specific growth rate and c) population composition with regards to producing cells (colored), low-producing (gray-colored) and non-producing cells (black-colored). Over a typical cultivation time line, these scenarios may be characterized by: case (1) stable increase in performance and increase in load (e.g. by homogenous, population-uniform change) (green-colored), case (2) stable performance despite a production load (e.g. by a low spontaneous formation rate of heterogeneity) (pink-colored), case (3) partial decline to intermediate lower level due to rising subpopulation that overcame the production load through producing at lower level (e.g. [55]) (yellow-colored), case (4) homogenous increase in performance that increases the production load, in turn leading to higher enrichment rate of heterogeneity (purple-colored), case (5) enrichment of heterogeneity driven by a load, leading to complete production decline (e.g., [27]) (blue-colored)
Fig. 2Strain engineering strategies for stabilization of long-term bioprocesses. Stabilization of long-term bioprocesses can be divided into mutation genotype-directed (bottom-up) strategies mitigating known recurring mutational genotypes e.g. informed by DNA-sequencing, and production phenotype-directed (top-down) strategies that provide a non-natural growth advantage to a desirable production phenotype, e.g. by coupling the pathway/product metabolically to essential metabolism or sensing for the pathway/product using genetically encoded biosensors
Detected pathway mutations and mutation genotype-directed stabilization strategies
| Mutation type | Host and product | Suggested stabilization strategy | Reference |
|---|---|---|---|
| SNPs, deletions | Essential gene fusion (sequence entanglement) | [ | |
| IS | Essential gene fusion (transcriptional coupling) | [ | |
| Large duplication | Deletion of recombinogenic IS repeats | [ | |
| Deletions | Avoid DNA repeats | [ | |
| IS | CRISPRi knockdown of IS | [ | |
| IS | IS deletion | [ | |
| Recombination | [ |
Optimized host organisms engineered to reduce effects from mutation-causing genes
| Organism | Targeted mutagenic component | Strategy | Reference |
|---|---|---|---|
| ISs, prophages | Deletion of all ISs and prophages | [ | |
| ISs | CRISPR-based abolishment by point mutation, conjugation of IS-less regions | [ | |
| ISs | CRISPRi knockdown of IS | [ | |
| ISs | CRISPRi knockdown of IS | [ | |
| ISs | Deletion | [ | |
| ISs, error-prone DNA polymerase | Deletion | [ | |
| IS | CRISPRi knockdown of IS | [ |
Published production phenotype-directed synthetic addictions, including systems relying on conditioned medium
| Organism | Product | Production stability (> 90%) (cell generations) | Growth controlling gene | Selective condition | Reference |
|---|---|---|---|---|---|
Fatty acids Tyrosine | No long-term serial-passaging cultivation | Leucine prototrophy Antibiotic resistance gene | Leucine depleted, Tetracycline | [ | |
| Mevalonic acid | 95 | Folate and peptidoglycan biosynthesis | None (self-selecting) | [ | |
Tryptophan Phenylalanine | No long-term serial-passaging cultivation | Toxin-Antitoxin system | None (self-selecting) | [ | |
| Vanillin-ß-glucoside | 55 | Glutamine prototrophy | Glutamine depleted | [ | |
| Naringenin | 320 | Leucine prototrophy | Leucine depleted | [ |
The reported stability of the production pathway is reported but the instability of the production phenotype also depends on the product (not comparable due to lacking production load measurements)